Contents

Targeting Type 2 Diabetes ................................................................. 1
Christina Schwanstecher and Mathias Schwanstecher

Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic
Therapies ................................................................. 35
Monique Heald and Michael A. Cawthorne

GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors .............. 53
Baptist Gallwitz

Cannabinoids and Endocannabinoids in Metabolic Disorders
with Focus on Diabetes .......................................................... 75
Vincenzo Di Marzo, Fabiana Piscitelli, and Raphael Mechoulam

SGLT Inhibitors as New Therapeutic Tools in the Treatment
of Diabetes ................................................................. 105
Rolf K.H. Kinne and Francisco Castaneda

Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1
in Antidiabetic Therapy .......................................................... 127
Minghan Wang

Nampt and Its Potential Role in Inflammation
and Type 2 Diabetes .......................................................... 147
Antje Garten, Stefanie Petzold, Susanne Schuster, Antje Körner,
Jürgen Kratzsch, and Wieland Kiess

Inhibition of Ganglioside Biosynthesis as a Novel Therapeutic
Approach in Insulin Resistance .............................................. 165
Jin-ichi Inokuchi
Overcoming Insulin Resistance with Ciliary Neurotrophic Factor  ...... 179
Tamara L. Allen, Vance B. Matthews, and Mark A. Febbraio

Thermogenesis and Related Metabolic Targets in Anti-Diabetic Therapy ................................................................. 201
Jonathan R.S. Arch

Interleukin-Targeted Therapy for Metabolic Syndrome and Type 2 Diabetes ................................................................. 257
Kathrin Maedler, Gitanjali Dharmadhikari, Desiree M. Schumann, and Joachim Størling

Fructose-1, 6-Bisphosphatase Inhibitors for Reducing Excessive Endogenous Glucose Production in Type 2 Diabetes ........ 279
Paul D. van Poelje, Scott C. Potter, and Mark D. Erion

AMP-Activated Protein Kinase and Metabolic Control ................... 303
Benoit Viollet and Fabrizio Andreelli

Mitochondria as Potential Targets in Antidiabetic Therapy .................. 331
Paula I. Moreira and Catarina R. Oliveira

Research and Development of Glucokinase Activators for Diabetes Therapy: Theoretical and Practical Aspects ............. 357
Franz M. Matschinsky, Bogumil Zelent, Nicolai M. Doliba, Klaus H. Kaestner, Jane M. Vanderkooi, Joseph Grimsby, Steven J. Berthel, and Ramakanth Sarabu

Index ................................................................................................................. 403
Diabetes - Perspectives in Drug Therapy
Schwanstecher, M. (Ed.)
2011, XIII, 408 p. 69 illus., Hardcover
ISBN: 978-3-642-17213-7